Take a look around.
Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg
Bayer, a leader in women's healthcare, announced today the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to potentially extend the...Learn more
CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics
CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of...Learn more
Explore Our Divisions
In line with our mission “Bayer: Science for A Better Life,” we aim to improve people’s quality of life.